Prilenia Therapeutics B.V., a developer of novel treatments for neurodegenerative and neurodevelopmental disorders, has raised $62.5 million in Series A financing. Forbion led the round with participation from other investors that included Morningside Venture Investments and Sectoral Asset Management.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: